Latest From Biotech Now
This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >
Get to Know GMOs month launches today @GMOAnswers! What is “Get to Know GMOs Month”? With 18 million Google search results for the term “GMO” alone and more than 200,000 tweets per month, it’s safe to say that GMOs are a topic on a lot of people’s minds. Each October, GMO Answers encourages you to “Get to Know GMOs” by diving into some of the most common questions and concerns about GMOs, as well as misconceptions. Since Read More >
Forbes’ Matthew Herper ran a guest post from Robert Nelsen, cofounder and managing director of ARCH Venture Partners, which addresses the challenges our industry is currently facing amid the continued need for biomedical innovation. Read it here.
This week, BIO announced the final program and speakers for the 14th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences. The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2016. The event will take place October 20-21, 2015, at the Parc 55 in San Francisco, California. “This year’s BIO Investor Forum features a compelling and Read More >
Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute. Dr. Gottlieb takes aim at the recent proposal offered by the campaign of Secretary Hillary Clinton to aggressively regulate the price of innovative prescription medicines. BIO shared many of those concerns in our statement and a related blog post. Dr. Gottlieb notes, “It’s important to distinguish between new medicines that are priced at Read More >